Andrew A Colin

University of Miami Miller School of Medicine, Miami, Florida, United States

Are you Andrew A Colin?

Claim your profile

Publications (91)351.16 Total impact

  • Giovanni A. Rossi · Michela Silvestri · Andrew A. Colin ·
    [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs (miRNAs) are small single-stranded RNA molecules involved in the regulation of gene expression at the post-transcriptional level. In the airways, miRNAs are implicated in the modulation of antiviral defense, through modulation of both innate and adaptive immune response in inflammatory and immune effector cells but also in parenchymal cells. The first target of respiratory viruses are airway epithelial cells. Following infection, an altered expression of distinct miRNAs occurs in airway cells aimed at inhibiting viral replication and preserving the airway epithelial barrier, while at the same time viruses induce or repress the expression of other miRNAs that favor viral replication. Understanding the changes in miRNA expression profile, identification of miRNAs target genes and their contribution to the pathogenesis of the disease may help the intricate mechanisms of virus-host interaction. Further understanding of these molecular mechanisms could lead to development of new antiviral treatments in common, high impact, respiratory disorders for which specific treatments are not available. Respiratory syncytial virus (RSV) airway infection is a common example of virus modifying miRNAs expression to favor immune evasion, and constitutes the salient feature of this review. Pediatr Pulmonol. © 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.
    Pediatric Pulmonology 04/2015; 50(7). DOI:10.1002/ppul.23193 · 2.70 Impact Factor
  • Shatha Yousef · George M Solomon · Alan Brody · Steven M Rowe · Andrew A Colin ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The underlying cause of cystic fibrosis (CF) is the loss of epithelial chloride and bicarbonate transport due to mutations in the CF transmembrane conductance regulator (CFTR) gene encoding the CFTR protein. Ivacaftor is a gene-specific CFTR potentiator that augments in vivo chloride transport in CFTR mutations affecting channel gating. Originally approved for the G511D CFTR mutation, ivacaftor is now approved for eight additional alleles exhibiting gating defects and has also been tested in R117H, a CFTR mutation with residual function that exhibits abnormal gating. P67L is a class 4 conductance (nongating) mutation exhibiting residual CFTR function. We report marked clinical improvement, normalization of spirometry, and dramatic reduction in radiographic structural airway changes after > 1 year of treatment with ivacaftor in a young adult with the compound heterozygous genotype P67L/F508del CFTR. The case suggests that ivacaftor may have a potential benefit for patients with CF with nongating mutations.
    Chest 03/2015; 147(3):e79-82. DOI:10.1378/chest.14-1198 · 7.48 Impact Factor
  • Andrew A Colin · Mitra Shafieian · Martin Andreansky ·
    [Show abstract] [Hide abstract]
    ABSTRACT: No abstract is available for this article.
    Pediatric Pulmonology 03/2015; 45(4):411. DOI:10.1002/ppul.21178 · 2.70 Impact Factor

  • Pediatric Allergy, Immunology, and Pulmonology 03/2015; 28(1):63-65. DOI:10.1089/ped.2014.0377 · 0.66 Impact Factor
  • Source
    Giovanni A Rossi · Andrew A Colin ·
    [Show abstract] [Hide abstract]
    ABSTRACT: There is evidence that respiratory viruses play a key role in the development and exacerbation of obstructive respiratory diseases in children. This review attempts to juxtapose the separate profiles and prototypes of pathogenenetic mechanisms represented by the two most common amongst such viruses: respiratory syncytial virus (RSV) and human rhinovirus (HRV). RSV represents the most common agent of severe airway disease in infants and young children, and is predominant in winter months. Large epidemiological studies have revealed an unequivocal relationship between RSV infection and subsequent wheezing into childhood, thought to be related to long-term changes in neuroimmune control of the airways rather than allergic sensitisation. HRV is a highly diverse group of viruses that affect subjects of all ages, is ubiquitous and occurs year-round. In contrast to RSV, infections with HRV cause minimal cytotoxicity but induce a rapid production of cytokines and chemokines with amplification of the inflammatory response. The susceptibility to HRV-induced bronchiolitis and subsequent wheezing appears to be linked to individual predisposition since it is often associated with a family or personal history of asthma/atopy. Thus, RSV probably serves as an "inducer" rather than a "trigger". Conversely, HRVs seem to serve as a "trigger" rather than an "inducer" in predisposed individuals.
    European Respiratory Journal 10/2014; 45(3). DOI:10.1183/09031936.00062714 · 7.64 Impact Factor
  • Andrew Colin · Elisa Basora · Shatha Yousef ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Nontuberculous mycobacteria (NTM) have been increasingly recognized in recent years as contributors to clinically significant lung infection in cystic fibrosis (CF) patients. Reports of prevalence vary from 6 to 22% around the world. Prevalence estimates in childhood CF is challenging since sputum producers are rare, bronchoalveolar lavage is an invasive procedure and may not be feasible, and mounting evidence deeming throat cultures to be unsuccessful in detecting NTM. We report a case of an overall healthy 13 year old young adolescent female with CF, who presented with Mycobacterium avium complex (MAC) as her first documented lung infection, and while only presenting with minor cough proved to have severe purulent bronchial infection. Contrary to common paradigms, NTM can be the first infection in a non-previously infected airway, and, this first infection can be of a serious nature unlike the more subtle anticipated pattern. The causes of the high and probably increasing overall incidence of NTM and specifically in CF elude explanation and mandate further study. Continuing efforts should be invested into the study of all aspects of this ominous infection. Pediatr Pulmonol. © 2014 Wiley Periodicals, Inc.
    Pediatric Pulmonology 09/2014; 50(3). DOI:10.1002/ppul.23101 · 2.70 Impact Factor
  • Source
    Andrew A Colin · Shatha Yousef · Erick Forno · Matti Korppi ·

    Pediatrics 05/2014; 133(6). DOI:10.1542/peds.2014-0871 · 5.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Suppurative complications of pneumonia such as empyema, lung abscess, pyopneumothorax, and necrotizing pneumonia (NP) are uncommon in children. Over the last decade an increasing incidence of NP has been reported. Streptococcus pneumoniae continues to be the predominant causative organism of NP, and while sporadic cases were reported prior to routine administration of heptavalent pneumococcal vaccine, a marked increase in NP appears to relate to replacement pneumococcal strains. Pleural involvement is almost universal in NP, and the course of pleural disease often determines its duration and outcome, particularly as it relates to complication of bronchopleural fistula. Cavities are formed in NP within the lung parenchyma and in the pleural space as the fibrosing pleural process organizes. The similarity of the radiologic appearance of parenchymal and pleural space cavities often makes the differentiation of pneumatocele versus residua of loculated pneumothorax challenging. The prevailing perception from most reports on childhood NP is of a favorable outcome with conservative approach. We report two pediatric cases with pneumonia who presented with prolonged fever despite antibiotic treatment, eventually diagnosed with NP. After stabilization on prolonged IV antibiotics, and weeks after discharge, they presented with unexpected acute respiratory failure due to a life-threatening tension air collection. In this article we discuss the nature of NP, its typical presentation, benign course and outcome, albeit its potential to cause serious late complications in the light of our recent experiences. Increasing awareness of such complications will result in more careful follow-up and in providing appropriate recommendations to parents of patients recovering from NP. Pediatr Pulmonol. © 2013 Wiley Periodicals, Inc.
    Pediatric Pulmonology 03/2014; 49(3). DOI:10.1002/ppul.22943 · 2.70 Impact Factor
  • Amir Kugelman · Andrew A Colin ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Late preterm (LP) infants are defined as those born at 34-0/7 to 36-6/7 weeks' gestational age. LP infants were previously referred to as near term infants. The change in terminology resulted from the understanding that these infants are not fully mature and that the last 6 weeks of gestation represent a critical period of growth and development of the fetal brain and lungs, and of other systems. There is accumulating evidence of higher risks for health complications in these infants, including serious morbidity and a threefold higher infant mortality rate compared with term infants. This information is of critical importance because of its scientific merits and practical implications. However, it warrants a critical and balanced review, given the apparent overall uncomplicated outcome for the majority of LP infants.Others reviewed the characteristics of LP infants that predispose them to a higher risk of morbidity at the neonatal period. This review focuses on the long-term neurodevelopmental and respiratory outcomes, with the main aim to suggest putative prenatal, neonatal, developmental, and environmental causes for these increased morbidities. It demonstrates parallelism in the trajectories of pulmonary and neurologic development and evolution as a model for fetal and neonatal maturation. These may suggest the critical developmental time period as the common pathway that leads to the outcomes. Disruption in this pathway with potential long-term consequences in both systems may occur if the intrauterine milieu is disturbed. Finally, the review addresses the practical implications on perinatal and neonatal care during infancy and childhood.
    PEDIATRICS 09/2013; 132(4). DOI:10.1542/peds.2013-1131 · 5.47 Impact Factor
  • J Reiter · N Demirel · A Mendy · J Gasana · E R Vieira · A A Colin · A Quizon · E Forno ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Macrolide antibiotics, which have anti-inflammatory and immune modulatory effects, have been studied as adjuncts for the management of asthma. However, results have been contradictory and trials underpowered. We therefore sought to conduct a meta-analysis of randomized controlled trials (RCT). All RCT of prolonged macrolides (3+ weeks) for asthma treatment, published up to January 2013 in MEDLINE, Scopus, CINAHL, Highwire, and The Cochrane Collaboration Library, were included. Fixed- or random-effects models were used to calculate pooled weighted or standard mean differences (WMD or SMD, respectively). A total of 12 studies were included for analysis. The pooled effect of macrolides on FEV1 (eight trials, 381 subjects) was not significant (SMD 0.05, 95% CI -0.14-0.25), but there was a significant increase in peak expiratory flow (four trials, 419 subjects; WMD 6.7, 95% CI 1.35-12.06). Pooled analysis also showed significant improvements in symptom scores (eight studies, 478 subjects; WMD -0.46, 95% CI -0.60 to -0.32), quality of life (five trials, 346 subjects; WMD 0.18, 95% CI 0.001-0.37), and airway hyper-reactivity (two trials, 131 subjects; SMD 1.99, 95% CI 0.46-3.52). Post hoc evaluation showed limited statistical power to detect significant differences in FEV1. Macrolide administration for asthma for three or more weeks was not associated with improvement in FEV1, but produced significant improvements in peak expiratory flow, symptoms, quality of life, and airway hyper-reactivity. Macrolides may therefore be beneficial as adjunct asthma therapy. Future trials, focusing on long-term safety and effectiveness, should use standardized outcomes and procedures.
    Allergy 07/2013; 68(8). DOI:10.1111/all.12199 · 6.03 Impact Factor

  • Paediatric respiratory reviews 07/2013; 14:S58. DOI:10.1016/S1526-0542(13)70066-6 · 2.20 Impact Factor
  • T. Ali-Dinar · A. Colin · M. Andreansky · J. Reiter ·

    Paediatric respiratory reviews 07/2013; 14:S77. DOI:10.1016/S1526-0542(13)70134-9 · 2.20 Impact Factor

  • Paediatric respiratory reviews 07/2013; 14:S72. DOI:10.1016/S1526-0542(13)70115-5 · 2.20 Impact Factor
  • E. Forno · N. Elazab · A. Mendy · J. Gasana · E.R. Vieira · A. Quizon · A. Colin ·

    Paediatric respiratory reviews 07/2013; 14:S55. DOI:10.1016/S1526-0542(13)70056-3 · 2.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The optimal strategy for monitoring cystic fibrosis (CF) lung disease in infancy remains unclear. Objective: To describe longitudinal associations between infant pulmonary function tests (iPFTs), chest radiograph (CXR) scores and other characteristics. Methods: CF patients ≤24 months old were enrolled in a 10-center study evaluating iPFTs 4 times over a year. CXRs ∼1 year apart were scored with the Wisconsin and Brasfield systems. Associations of iPFTs with clinical characteristics were evaluated with mixed effects models. Results: The 100 participants contributed 246 acceptable flow/volume (FEV0.5, FEF75), 303 functional residual capacity (FRC) measurements and 171 CXRs. Both Brasfield and Wisconsin CXR scores worsened significantly over the 1 year interval. Worse Wisconsin CXR scores and S. aureus were both associated with hyperinflation (significantly increased FRC) but not with diminished FEV0.5 or FEF75. Parent-reported cough was associated with significantly diminished FEF75 but not with hyperinflation. Conclusions: In this infant cohort in whom we previously reported worsening in average lung function, CXR scores also worsened over a year. The significant associations detected between both Wisconsin CXR score and S. aureus and hyperinflation, as well as between cough and diminished flows, reinforce the ability of iPFTs and CXRs to detect early CF lung disease.
    European Respiratory Journal 05/2013; 42(6). DOI:10.1183/09031936.00138412 · 7.64 Impact Factor
  • Eman S Al-Khadra · Kin-wai Chau · Cara Pizzo Barone · Andrew A Colin ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Herein we describe three infants with the rare presentation of pneumonia with septic shock as their initial medical encounter leading to the diagnosis of cystic fibrosis (CF). At the time of their presentation all three children had significant nutritional deficiency. We initiated an aggressive treatment regimen including nutritional supplementation which resulted in improvement in their pulmonary status and no further recurrences. This series highlights the possible presentation of CF in infancy as a life-threatening invasive infection of Staphylococcus aureus or Pseudomonas aeruginosa. It also supports neonatal screening and emphasizes the role of early attention to nutritional status and vitamin supplementation. Pediatr Pulmonol. 2012; 47:722–726.
    Pediatric Pulmonology 07/2012; 47(7):722-6. DOI:10.1002/ppul.21611 · 2.70 Impact Factor
  • N. Demirel · A. Quizon · E. Beltetón · J. Reiter · A. Colin ·

    Paediatric respiratory reviews 06/2012; 13:S58. DOI:10.1016/S1526-0542(12)70080-5 · 2.20 Impact Factor
  • Annabelle Quizon · Predrag Minic · Petr Pohunek · Asher Tal · Andrew A Colin ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Previous reports have described structural airway abnormalities in children with non-cystic fibrosis chronic suppurative lung disease as well as obliterative membranes in the major bronchi of cystic fibrosis patients. The putative paradigm proposed in the evolution of these membranes invokes intense inflammation resulting in granulation tissue and neovascularization with the formation of pyogenic granuloma and eventually fibrosis. Our series of four cases widens the spectrum of conditions that may be conducive to large airway obliteration to include non-suppurative chronic infections and possibly immunosuppression. Obliteration of lumina in proximal and distal airways was visualized on bronchoscopy, the latter by the use of the ultrathin bronchoscopes. An attempt at invasive intervention by transbronchial breaching of the obstruction was unsuccessful in three cases, and in one case, the obliterative process resolved spontaneously and without any radiologic trace, presumably by resorption or rupture or through development of collateral ventilation. This series highlights the use of bronchoscopy for diagnosis and occasionally for therapeutic intervention in hitherto little recognized obliterative airway lesions. These acquired obliterative lesions should be considered in the evaluation of patients with isolated non-resolving pulmonary infiltrates or other conditions in which bronchial and bronchiolar patency may be impaired. Pediatr Pulmonol. © 2013 Wiley Periodicals, Inc.
    Pediatric Pulmonology 06/2012; 49(3). DOI:10.1002/ppul.22775 · 2.70 Impact Factor
  • A.A. Colin · E.V. Kontopoulos · J. Reiter · R.A. Quintero ·

    Paediatric respiratory reviews 06/2012; 13:S1. DOI:10.1016/S1526-0542(12)70003-9 · 2.20 Impact Factor
  • A. Quizon · A.A. Colin · G.A. Rossi ·

    Paediatric respiratory reviews 06/2012; 13:S13–S14. DOI:10.1016/S1526-0542(12)70016-7 · 2.20 Impact Factor

Publication Stats

1k Citations
351.16 Total Impact Points


  • 2009-2015
    • University of Miami Miller School of Medicine
      • Department of Pediatrics
      Miami, Florida, United States
  • 2006-2015
    • University of Miami
      • • Miller School of Medicine
      • • Department of Pediatrics
      كورال غيبلز، فلوريدا, Florida, United States
  • 2013
    • Miami University
      Оксфорд, Ohio, United States
  • 1996-2009
    • Boston Children's Hospital
      • • Department of Radiology
      • • Division of Adolescent Medicine
      • • Department of Pediatrics
      Boston, Massachusetts, United States
  • 1989-2006
    • Harvard Medical School
      • • Department of Medicine
      • • Department of Pediatrics
      Boston, Massachusetts, United States
  • 2005
    • Beth Israel Deaconess Medical Center
      Boston, Massachusetts, United States
  • 2001
    • Mount Sinai School of Medicine
      • Department of Pediatrics
      Manhattan, NY, United States